Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.
Anis Hamid, MBBS
Advertisement
Articles by Anis Hamid, MBBS
Anis Hamid, MBBS, discusses next steps for precision medicine in metastatic hormone sensitive prostate cancer.
Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.
Anis Hamid, MBBS, discusses the hypothesis of predictive biomarkers for newly diagnosed metastatic hormone sensitive prostate cancer.
Anis Hamid, MBBS, discusses the progression of therapy for metastatic prostate cancer.
Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the potential predictive value of the luminal B subtype as a biomarker of response to docetaxel in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
Advertisement
Latest Updated Articles
Dr. Hamid on a Potential Biomarker of Response to Docetaxel in mHSPCPublished: February 25th 2020 | Updated:
Dr. Hamid on the Progression of Therapy for Metastatic Prostate CancerPublished: March 17th 2020 | Updated:
Dr. Hamid on the Exploration of Predictive Biomarkers in mHSPC SubtypesPublished: March 20th 2020 | Updated:
Dr. Hamid on the Evolution of Precision Medicine in Prostate CancerPublished: April 3rd 2020 | Updated:
Dr. Hamid on Next Steps for Precision Medicine in mHSPCPublished: April 24th 2020 | Updated:
Dr. Hamid on Potential Combinations With Docetaxel in mHSPC SubtypesPublished: April 30th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5